INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 445m ago
HOUSE PTR45m ago
SEC 13F45m ago
ROBINHOOD CHAIN45m ago
Public company

Pelthos Therapeutics Inc.

PTHSCIK 0001919246

EDGAR filingsOpen in network
Price$9.36
1 year-74.7%
Disclosed transactions24
Buys / sells2 / 18
Max Insider Score47
Connections with evidence9

PTHS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
11
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$17K
797 sh
Oct 2, 2026Oct 6, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Holds over 5% ofevidence
    LIGAND PHARMACEUTICALS INC49.9% of class · Schedule 13D · Nov 2, 2026
  • ← Insider ofevidence
    Davis Todd CDirector · Jun 15, 2026
  • ← Insider ofevidence
    Francis Knuettel IICFO, Treas & Secty · May 26, 2026
  • ← Insider ofevidence
traded Oct 2, 2026
+4d
SEC FORM 4

Evidence

11
FM
Friedberg Ezra MDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$12K
558 sh
Oct 2, 2026Oct 6, 2026
traded Oct 2, 2026
+4dSEC FORM 4

Evidence

15
PM
Pauls MatthewDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$17K
786 sh
Oct 2, 2026Oct 6, 2026
traded Oct 2, 2026
+4dSEC FORM 4

Evidence

17
FM
Friedberg Ezra MDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$656
24 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

17
PM
Pauls MatthewDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$18K
692 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

17
FM
Friedberg Ezra MDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$14K
534 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

17
PM
Pauls MatthewDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$2,572
94 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

17
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$2,318
85 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

17
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$19K
712 sh
Jul 2, 2026Jul 7, 2026
traded Jul 2, 2026
+5dSEC FORM 4

Evidence

29
DC
Davis Todd CDirector
PTHSPelthos Therapeutics Inc.
Open-market purchase
BUY$14K
503 sh
Jun 11, 2026Jun 15, 2026
traded Jun 11, 2026
+4dSEC FORM 4

Evidence

47
DC
Davis Todd CDirector
PTHSPelthos Therapeutics Inc.
Open-market purchase
BUY$986K
35.4K sh
Jun 11, 2026Jun 15, 2026
traded Jun 11, 2026
+4dSEC FORM 4

Evidence

9
FK
Francis Knuettel IICFO, Treas & Secty
PTHSPelthos Therapeutics Inc.
Grant or award
A—
59.5K sh
May 22, 2026May 26, 2026
traded May 22, 2026
+4dSEC FORM 4

Evidence

25
FK
Francis Knuettel IICFO, Treas & Secty
PTHSPelthos Therapeutics Inc.
Open-market sale
SELL$40K
1,500 sh
May 22, 2026May 26, 2026
traded May 22, 2026
+4dSEC FORM 4

Evidence

21
FK
Francis Knuettel IICFO, Treas & Secty
PTHSPelthos Therapeutics Inc.
Disposition to issuer
D—
13.9K sh
May 22, 2026May 26, 2026
traded May 22, 2026
+4dSEC FORM 4

Evidence

9
FK
Francis Knuettel IICFO, Treas & Secty
PTHSPelthos Therapeutics Inc.
Disposition to issuer
D—
42.5K sh
May 22, 2026May 26, 2026
traded May 22, 2026
+4dSEC FORM 4

Evidence

20
PM
Pauls MatthewDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$8,514
415 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence

20
PM
Pauls MatthewDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$7,926
371 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence

20
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$8,616
420 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence

20
MR
Malamut RichardDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$6,359
310 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence

20
MR
Malamut RichardDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$5,981
280 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence

20
FM
Friedberg Ezra MDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$6,010
293 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence

20
FM
Friedberg Ezra MDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$5,661
265 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence

20
GP
Greenleaf PeterDirector
PTHSPelthos Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$8,053
377 sh
Apr 2, 2026Apr 6, 2026
traded Apr 2, 2026
+4dSEC FORM 4

Evidence

15
EJ
Einhorn Andrew J.Director
PTHSPelthos Therapeutics Inc.
Grant or award
A—
12.0K sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence

Malamut Richard
Director · Apr 6, 2026
  • ← Insider ofevidence
    Pauls MatthewDirector · Apr 6, 2026
  • ← Insider ofevidence
    Greenleaf PeterDirector · Apr 6, 2026
  • ← Insider ofevidence
    Friedberg Ezra MDirector · Apr 6, 2026
  • ← Insider ofevidence
    Einhorn Andrew J.Director · Dec 29, 2025

    • Planned sales and 5% stakes

    Form 144, 13D and 13G
    • LILigand Pharmaceuticals IncorporatedMay seek to influence the company · crossed on Oct 30, 2026 · 5.19M shares49.9% of class13D amendment · filed Nov 3, 2026